CCH® Tagetik



CCH® Tagetik case study

From manual consolidation to global financial control: How IBSA standardized reporting across 20+ subsidiaries

By replacing Excel-based processes with a unified finance platform, IBSA streamlined consolidation, automated intercompany reconciliations, and improved visibility across its global organization.

Company

IBSA Institut Biochimique SA

Industry

Manufacturing

Uses of CCH® Tagetik software

- CCH Tagetik Standard Platform
- CCH Tagetik Financial Close and Consolidation
  - Fast Close
- CCH Tagetik Lease Accounting
  - IFRS16
- CCH Tagetik Global Minimum Tax

"Our projects originated from the need to streamline and accelerate consolidation processes that, until a few years ago, were managed entirely through manual Excel-based activities."

Maria Grazia Manno, Group Reporting Team at IBSA

The challenge

As IBSA continued to expand its international footprint, managing financial consolidation through spreadsheets became increasingly difficult. Financial data had to be collected, validated, and reconciled across a growing network of subsidiaries, creating significant manual effort and increasing the risk of errors.

The reliance on disconnected processes also limited visibility and made it difficult to apply consistent reporting standards across the Group. Finance needed a more scalable approach that could support growing reporting requirements while improving efficiency, control, and collaboration between Corporate Finance and local teams.

The objectives

IBSA sought to modernize its consolidation and reporting processes by:

- Reducing risk associated with manual spreadsheet-based activities
- Accelerating group consolidation and financial close cycles
- Standardizing reporting processes across the organization
- Increasing accountability for data quality at the subsidiary level
- Automating the collection of disclosures required for statutory reporting and financial statements
- Providing Finance with greater visibility and control across the reporting process

IBSA

CCH Tagetik case study

Company facts

- 2,500+ employees worldwide across more than 90 countries
- More than 20 subsidiaries
- Operations across 10 therapeutic areas
- Over 160 professionals dedicated to Research & Development

Requirements

- Automate Group financial consolidation processes
- Centralize financial data collection from international subsidiaries
- Improve the efficiency and control of intercompany reconciliations
- Support both statutory and management reporting through a single platform
- Enhance collaboration between Corporate Finance and local finance teams

Benefits & results

- 25-30 users collaborating in a single finance platform
- Consolidation, budgeting, and forecasting unified in one solution
- Automated intercompany reconciliations improve efficiency and control
- Decentralized disclosure collection increases subsidiary accountability
- Improved visibility into reporting exceptions and process status
- Implementation completed in approximately 12 months

The solution

IBSA selected CCH® Tagetik to digitize and standardize its financial consolidation and reporting processes.
Implemented in approximately 12 months, the solution now supports monthly, quarterly, and annual consolidation activities while also providing a single platform for budgeting, forecasting, management reporting, and financial statement disclosures.

Today, 25-30 users across the organization collaborate within a shared environment, using standardized workflows and templates to submit, validate, and review financial information. This approach enables Corporate Finance to monitor process status in real time, improve data quality, and quickly identify reporting exceptions that require attention.

Benefits & Results

Streamlined Consolidation and Close Engagement
By replacing Excel-based processes with automated workflows and embedded controls, IBSA significantly reduced manual effort while creating a more efficient and governed consolidation process.

Improved Data Quality and Accountability
Standardized templates enable subsidiaries to enter and validate information directly within the platform, improving data accuracy and increasing ownership across local finance teams.

Faster Intercompany Reconciliations
Automated reconciliation capabilities help teams quickly identify and resolve discrepancies between entities, accelerating the close process and strengthening financial control.

Consistent Reporting Across the Group
A unified reporting framework has standardized the collection, validation, and analysis of financial information across subsidiaries, supporting greater consistency and transparency.

Better Visibility for Decision-Making
Access to consolidated financial and operational information provides management with deeper insights into performance across products, markets, and therapeutic areas.

Greater Collaboration Across Finance
By decentralizing selected disclosure and reporting activities, IBSA reduced the administrative burden on the central consolidation team while encouraging greater participation from subsidiaries throughout the reporting process.

About IBSA

Founded in Lugano, Switzerland, in 1945, IBSA (Institut Biochimique SA) is a multinational pharmaceutical company with a presence in more than 90 countries across five continents and 20 subsidiaries throughout Europe, China, and the United States. The Group generates net revenues of CHF 886 million and employs more than 2,500 people across its headquarters, subsidiaries, and manufacturing facilities. IBSA's broad product portfolio spans 10 therapeutic areas, including reproductive medicine, endocrinology, pain and inflammation, musculoskeletal health, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic care, respiratory health, and consumer health. The company is also recognized as a global leader in reproductive medicine and among the world's leading manufacturers of hyaluronic acid-based products. IBSA's corporate philosophy is built on four core pillars: People, Innovation, Quality, and Responsibility. ibsaitaly.it

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2025 annual revenues of €6.1 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,100 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit **www.wolterskluwer.com** , follow us on **Facebook**, **LinkedIn**, and **YouTube**

CCH® Tagetik
by Wolters Kluwer